By Anthony O. Goriainoff

 

Arecor Therapeutics PLC said Monday that its insulin candidate for diabetes, AT278, met all primary and secondary endpoints with positive headline results from the Phase 1 clinical trial.

The London-listed biopharmaceutical company--backed by Unilever PLC--said AT278 had the potential to significantly improve post prandial glucose control and reduce the injection volume and/or number of daily injections of people with diabetes who have a high daily insulin need.

"These positive data for AT278, the second product in our diabetes franchise, follow the earlier positive results from the Phase I clinical trial of AT247... Together they position Arecor with a unique combination of ultra-concentrated and ultra-rapid insulin candidates offering the potential to meet the broad needs of patients across the growing diabetes market," Chief Executive Sarah Howell said.

 

Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com

 

(END) Dow Jones Newswires

September 20, 2021 03:16 ET (07:16 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Unilever (NYSE:UL)
Historical Stock Chart
From Nov 2021 to Dec 2021 Click Here for more Unilever Charts.
Unilever (NYSE:UL)
Historical Stock Chart
From Dec 2020 to Dec 2021 Click Here for more Unilever Charts.